Lucid Group secures new investment from Intermediate Capital Group

Healthcare communications company Lucid Group has announced that it has secured new investment from Intermediate Capital Group (ICG). ... Private equity firm LDC will end its investment in Lucid after nearly four years, during which time Lucid has

Pfizer, BioNTech set to price COVID-19 vaccine ‘well below typical market rates’

We’ve tried to pursue a balanced approach that recognises that innovation requires capital and investment, so we plan to price our vaccine well below typical market rates reflecting the situation

Coronavirus disruption scuppers Curium Pharma sale

Three potential buyers for Curium – said to include investment groups Nordic Capital, Bain Capital and CVC Capital Partners – are said to have lowered their bids for France-based Curium amid turmoil

AstraZeneca launches $1bn Chinese investment fund

ups. The Healthcare Industrial Fund, set up with and led by investment bank China International Capital Corporation (CICC), will focus initially on companies at the Wuxi International Life Science Innovation Campus, ... The announcement of the new

Hancock says UK will consider mandatory vaccinations

Hospital investment. The revelation almost threatened to distract attention from the Conservatives’ flagship health policy statement at the conference, namely that the government intends to spend £13bn ($16bn) on capital investment ... NHS

The changing nature of approvals – what does the future hold?

High-profile disinvestments include those by Pfizer and Eli Lilly. However, Pfizer has since announced that, together with investment firm Bain Capital, it has created a new drug company called Cerevel ... Regulatory processes in Mainland China have

European biotech: a new generation of leaders emerges

This include specialist venture capital firms, which are upping their investment in the region, which is seen as underdeveloped compared to the sometime overheated Massachusetts and California biotech markets. ... As venture capital (VC) investors,

Biopharma's Future: Made in China

to encourage a home-grown pharma industry, as well as investment from multinational giant. ... Money flowing into Europe. Meanwhile, just as multinationals are increasing their investments in China, there is also a huge amount of investment capital

Drug pricing

European venture funding for the life science sector

The greater risk - given the inelasticity of the supply of R&D to the sudden increase in capital - is a lowering of the quality bar as marginal companies obtain investment. ... Keeping the bar high. To guard against this risk, it is essential that

Anish Mehta appointed CEO of new women's health business

Will head up the former Teva portoflio CVC Capital Partners recently acquired. ... London-based investment firm CVC Capital Partners has appointed Anish Mehta as chief executive officer of the international women’s health assets portfolio it acquired

David Horn Solomon takes the helm of Akari Therapeutics

Sanofi.”. His other roles have included CEO at Bionor Pharma and most recently he was at Nordic healthcare investment group Sund Capital where he was a managing partner.

IGEM Therapeutics appoints Dr Tim Wilson as CEO

has raised £2m from Epidarex Capital, in order to progress its pipeline of IgE antibody drug candidates. ... Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity

BMS appoints three independent directors

Samuels also brings considerable business and operational experience to the position, with a particular expertise in economics, capital markets and investment decision-making. ... He currently serves as a director at Perrigo Company and Stamps.com, and

Dr Stephen Hoffman joins Bicycle Therapeutics

Dr Hoffman brings 30 years of experience in the pharmaceutical and financial industries to the biotech, currently serving as a senior advisor to PDL BioPharma and president of 10x Capital, an ... investment management firm.

LUCID GROUP PARTNERS WITH NEW INVESTOR ICG

Lucid Group has secured a new investment from Intermediate Capital Group (ICG) to support its continued ambition to build a global business that delivers life transforming value for everyone. ... ICG brings deep healthcare sector expertise, a global

Newcells Biotech secures over £5m for 3D tissue models

Newcells Biotech have received multi-million investment to develop their pioneering 3D tissue models. ... The funding comes from two existing backers. Mercia has invested from its Northern Venture Capital Trust (VCT) and Enterprise Investment Scheme (EIS)

Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma and create a unique and unrivaled launch excellence offering

Envision’s acquisition of Two Labs follows the recent announcement of GHO Capital’s increased investment in the company and the backing of management for its continued global expansion. ... Tel: 1 614 389 4004. About GHO Capital. Global Healthcare

Envision Pharma Group

Acquisition follows increased investment in Envision from GHO Capital and its partners. ... GHO Capital and management acquire Ardian majority stake in Envision Pharma Group to accelerate continued growth.